LANDI-UP: Strengthening Confidence in Landiolol for Real-World ICU and Critical Care

2026 10 Mar

The LANDI-UP study provides the first European real-world evidence of landiolol use in critically ill patients with supraventricular arrhythmias. This landmark multicentre observational study demonstrates that landiolol achieves effective heart rate control with minimal haemodynamic impact, confirming its safety and efficacy across diverse Europ1 Read more

ASH 2025: New Insights on Rare Blood Cancer Treatments

2025 07 Dec

Hemato-oncology trials: AOP Health presents new results at top congress ASH AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases presented the results of two scientific investigations at the 67th American Society of Hematol1 Read more

Vasopressin in 2025: Emerging Data Converge on Earlier, Smarter Intervention

2025 03 Dec

Vasopressin, an adjunctive vasopressor agent in septic shock, is increasingly supported by evidence favouring early, targeted intervention. Recent research, from mechanistic reviews to artificial intelligence-driven modelling, converges on a coherent strategy: initiate vasopressin earlier, at lower norepinephrine doses, and before severe metabol1 Read more

Redefining Rate Control Strategy With Landiolol: Manage the Rhythm Without Compromising the System

2025 14 Oct

Landiolol, an ultra-short-acting and highly β1-selective intravenous β-blocker, addresses the need for rapid and controllable arrhythmia suppression while maintaining cardiovascular stability. Recently approved in the United States and already in use in Europe, landiolol combines rapid onset and offset with a favourable haemodynamic profile. 1 Read more

Vasopressin in Septic Shock: New Insights on Timely Addition to Norepinephrine

2025 24 Jul

Early vasopressin initiation in septic shock may improve outcomes beyond the current practice of waiting for higher norepinephrine doses. Recent studies suggest starting AVP earlier can reduce shock duration and hospital mortality. Despite AVP often being started late, a proactive, protocol-driven approach that considers Nor dose, duration, and 1 Read more

AOP Health Announces U.S. Availability of Rapiblyk™ (landiolol) for Critical Care Use

2025 21 Jul

Rapiblyk™ now available for order by healthcare providers in the U.S. Cencora   AOP Orphan Pharmaceuticals GmbH (AOP Health) today announced that Rapiblyk™ (landiolol), an ultra-short-acting, selective beta-1 adrenergic receptor blocker, is now commercially available in the United States and can be ordered through Cencora. This follows the U1 Read more

AOP Health Appoints John Kimmet as U.S. General Manager

2025 23 Jun

Veteran pharmaceutical executive to lead AOP Health’s U.S. expansion and commercial launch of Rapiblyk™   AOP Orphan Pharmaceuticals GmbH (AOP Health), a global leader in integrated therapy solutions for rare diseases and critical care, is pleased to announce the appointment of John Kimmet as U.S. General Manager. John brings more than 25 ye1 Read more

Rare Diseases Expert AOP Health Expands Leadership Team

2025 17 Jun

AOP Health Appoints New Vice Presidents to Drive Innovation, Digital Transformation, and Global Growth   To support its ambitious growth agenda, AOP Health is expanding its leadership team. The company has appointed three new Vice Presidents in key strategic areas: Zoltán Magyarics will lead Research & Development, Bernhard Seiser will overs1 Read more

Advancing Cardiovascular Management in Critical Care: A Focus on Vasopressors and Beta-Blockers

2025 20 May

Clinical insights on the use of beta-blockers and vasopressors in the ICU, focusing on landiolol and vasopressin.   When managing cardiovascular instability in critically ill patients, intensivists often face a delicate balancing act: controlling heart rate without compromising haemodynamics and maintaining perfusion without excessive va1 Read more

Rare Diseases: How Drug Shortages Threaten Patients

2025 06 May

Out of Stock, Limited Options: How Drug Shortages Threaten Rare Disease Patients Imagine living with a chronic, rare disease, and that your health depends on a specific medication. Then, one day, it turns out to be unavailable. You do not know when it might be on-stock again, there are only limited alternatives, and the future looks uncertain. 1 Read more

Less is More in Shock Management

2025 06 May

Permissive hypotension, phenotyping shock, vasopressor selection and timing, and emerging interest in beta-blockade for septic patients.   It is important to reconsider conventional aggressive approaches to shock management and explore the evolving concept of permissive hypotension. There is a need to avoid reflexively treating all hypot1 Read more

Rationale for Early Arginine-Vasopressin Administration

2025 27 Mar

The basics of vasopressor support and advanced considerations regarding its early use in intensive care settings.   Introduction The use of vasopressors in critical care is a crucial aspect of haemodynamic management. While norepinephrine remains the primary agent of choice, the role of other vasopressors such as vasopressin has ga1 Read more

From Invisibility to Insight: Data Unlocks New Potential in Rare Disease Research

2025 24 Feb

  Rare diseases present a striking paradox: individually they are often overlooked, yet together, they affect over 300 million people worldwide. Without data, their true impact on those affected and on the healthcare system remains invisible - making research, treatment development, and patient advocacy even more challenging. On February 28th, 1 Read more

Rare Disease Day 2025: New Podcast Series Supports Those Affected

2025 30 Jan

  February 28 is dedicated to Rare Disease Day, a global initiative to raise awareness about the challenges faced by people living with rare diseases. Around 400,000 Austrians are affected by rare diseases. The new podcast series in German language "Ab jetzt ist alles anders? Leben nach und mit einer schwerwiegenden Diagnose.“ ("Will everythin1 Read more

AOP Health Fills New Leadership Positions

2024 17 Dec

The globally operating pharmaceutical company AOP Health is gearing up for continued growth. To this end, the new position of Vice President of Market Access, Public Affairs & Patient Advocacy has been created and filled, while the role of Area Director DACH has been reassigned.   Mag. Bettina Bernhard, MIM MBA, became Vice President of M1 Read more

Rethinking Septic Shock Management: Potential of Early Vasopressin Use to Enhance Patient Outcomes

2024 28 Nov

Vasopressin timing, patient selection, optimal vasopressin use in septic shock, and potential mortality benefits in selected patient populations.   Septic Shock Overview and Current Treatments Septic shock is a severe, life-threatening response to infection, characterised by systemic inflammation, tissue hypoperfusion, and persisten1 Read more

U.S. FDA approves AOP Health’s Rapiblyk™

2024 27 Nov

  U.S. FDA approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the critical care setting.   AOP Orphan Pharmaceuticals GmbH (AOP Health) , based in Vienna, Austria, announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for Rapiblyk TM  (landiolol) in the hospital cr1 Read more

Pulmonary Hypertension Survey Reveals Needs of Family Caregivers

2024 18 Nov

PH Awareness Month: survey results generated strong interest at European Respiratory Society (ERS) Congress   PHA Europe presented the results of a patient survey 1  conducted in cooperation with AOP Orphan Pharmaceuticals GmbH (AOP Health) and OrphaCare in a poster presentation at the annual ERS congress in Vienna in September. The survey i1 Read more

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

2024 01 Oct

  AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with soli1 Read more

ESICM Webinar – Cardiovascular Management After Surgery

2024 01 Oct

  In a webinar at the ESICM Congress, Dr Aretha and Dr Garcia-Alvarez spoke about cardiovascular management after surgery. More specifically, Dr Aretha spoke about the management of post-operative atrial fibrillation, and Dr Garcia-Alvarez spoke about the importance of early application of vasopressin in septic shock patients.   Mana1 Read more

AOP Health Presents Podcast for Newly Diagnosed Patients

2024 25 Sep

  September is MPN Awareness Month. These four weeks are dedicated to a group of rare blood cancers called myeloproliferative neoplasms (MPN) and meant to put an emphasis on the challenges faced by patients affected. The Austrian pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health), specializing in the research and development of1 Read more

Building a Competitive and Attractive Pharmaceutical Ecosystem in the EU

2024 25 Sep

  On Tuesday 24 September, Alexander Natz, Secretary General of the European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE), sent a letter to the President of the European Commission Ursula von der Leyen, President of the European Parliament Roberta Metsola, and President of the European Council Charles Michel, outlining our vision for1 Read more

Sepsis is Always an Emergency

2024 05 Sep

Sepsis causes 20 percent of deaths worldwide: take immediate action if suspected.   Sepsis is responsible for around one fifth 1  of deaths worldwide. The disease is caused by an excessive reaction of the immune system, which subsequently turns against its own body. Because the symptoms are non-specific, sepsis is often detected very late, p1 Read more

AOP Health: Dietmar Eglhofer Appointed New Director Employee Experience & People Analytics

2024 22 Aug

  The international pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health), a member of the AOP Health Group, is increasingly investing in the optimization of the "employee experience", i.e. how employees perceive the company. To make its HR processes and services more data driven, the company is also focusing on "people analytics"1 Read more

AOP Health New Cancer Trial

2024 06 Aug

  A new therapeutic approach to fight cancer   With the approval of its Phase-1 clinical trial SERONCO-1, AOP Health has reached another milestone in its growth story. To mark the start of the trial at Vall d’Hebron University Hospital in Barcelona AOP Health hosted a panel discussion in collaboration with the daily Austrian newspaper “Der S1 Read more

Hematology/Oncology: New Results from Clinical Research Program

2024 10 Jun

  Hematology/oncology: AOP Health’s expanding clinical research program delivers new results.   AOP Orphan Pharmaceuticals GmbH (AOP Health) continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association (EHA) 2024 hybrid congress in Madrid, Spain1 Read more

Introduction to Landiolol in Acute Cardiac Care

2024 12 Mar

  An overview of landiolol, a potent and cardioselective beta-blocker offering a promising addition to the armamentarium for managing acute cardiac conditions for rapid and effective rate control with minimal adverse effects.   Cardiac emergencies present complex challenges in emergency medical settings, requiring prompt and effective ma1 Read more

Rare Diseases: No Innovative Therapies Without Research

2024 20 Feb

  Individualized therapies and the integration of the patient's perspective are becoming increasingly important.   February 29 is Rare Disease Day. On this occasion, the Austrian pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health) takes a look at the challenges faced by patients with rare diseases and highlights the trends1 Read more

AOP Health Receives Market Authorization for Landiolol in Canada

2023 13 Dec

At the end of November 2023, AOP Orphan Pharmaceuticals GmbH ( AOP Health ), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada) for its ultra-short-acting, cardioselective β1-blocker Landiolol. The drug is used in intensive care to treat atrial fibrillation and atrial flutt1 Read more

Planned EU Pharmaceutical Legislation Could Complicate Development of Rare Disease Therapies

2023 12 Dec

The entire EU pharmaceutical legislation is currently being negotiated. Among the regulations to be redefined are those concerning rare diseases. Experts fear that the planned changes – in particular by shortening protection periods – will lower the incentive for companies to conduct research in the field of rare diseases. This would reduce the av1 Read more

Blood Cancer: AOP Health Announces New Findings in Patients with Polycythemia Vera

2023 07 Dec

Presented at the American Society of Hematology (ASH) 65th annual meeting   AOP Orphan Pharmaceuticals GmbH (AOP Health), Vienna, Austria, announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythemia vera (PV) 1  The1 Read more

Bianca Tan is Therapeutic Area Director of Cardiology and Pulmonology

2023 06 Dec

AOP Health: Bianca Tan Assuming New Position as Therapeutic Area Director Cardiology and Pulmonology.   In 2006, Bianca Tan started her career at AOP Orphan Pharmaceuticals GmbH (AOP Health), an Austrian pharmaceutical company with headquarters in Vienna that specializes in rare diseases and intensive care medicine. She has worked in various d1 Read more

Cardiovascular Management in Septic Shock: Optimising Vascular and Cardiac Function

2023 30 Nov

An overview of vasopressor management, current evidence on its use, when to initiate vasopressor therapy for best possible patient outcome and a discussion regarding the use of landiolol in septic patients with persistent tachycardia.    Optimising Vasopressin Initiation in Septic Shock   Patients with septic shock, and especially1 Read more

Collaborative Research Ensures Availability of Rare Disease Therapies

2023 14 Nov

To ensure the availability of new therapies for rare diseases, a functioning cooperation between the public sector, academic research and research-based companies is crucial. With this in mind, Vienna's City Councilor for Health, Social Affairs and Sport, Peter Hacker, paid the Austrian pharmaceutical company AOP Orphan Pharmaceuticals GmbH ("AOP 1 Read more

AOP Health: Roland Bindeus becomes Senior Director Commercial

2023 08 Nov

The Vienna-based pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health), which specializes in rare diseases and critical care medicine ,  is repositioning itself strategically. In order to offer patients and healthcare professionals state-of-the-art therapy concepts not only today, but also in the future, AOP Health is introducing new1 Read more

AOP Health ESICM Congress 2023 Lunch Satellite Symposium

2023 18 Oct

AOP Health is devoted to long-term commitment, high quality, and continuity. Its vision is to be the most trusted company for advanced and innovative therapies in cardiology and pulmonology, haemato-oncology, critical care, neurology and metabolic disorders and rare diseases.   Join us for the AOP Health ESICM Congress 2023 Lunch Satellite Sym1 Read more

Cardiovascular Management in Sepsis: Improving Cardiac and Vascular Functions

2023 13 Oct

Vasopressin and landiolol are critical therapies for ensuring the vascular and cardiac systems are as close to optimal conditions as possible during septic shock. Better cardiovascular management in septic shock can help improve septic shock management.     Sepsis is a life-threatening organ dysfunction caused by a dysregulated host resp1 Read more

World Sepsis Day: Understanding Symptoms Better

2023 08 Sep

World Sepsis Day falls on September 13. Sepsis, which kills more people in Austria each year than heart attacks, is caused by an infection which spreads through the body and damages our organs. A lot of people in the general public still do not know very much about this issue.   Sepsis is one of the most common causes of death around the world1 Read more

Marion Rottenberg is the New International Patient Advocacy Lead at AOP Health

2023 29 Aug

The Vienna native has a wealth of experience in pharma and will be building up the European pioneer’s area of Patient Advocacy in the field of rare diseases and intensive care.   As of June 2023, Marion Rottenberg has taken over the role of International Patient Advocacy Lead at AOP Health. In this position, she is responsible for the strate1 Read more

Tachycardia in Sepsis: Friend or Foe?

2023 13 Mar

An overview of tachycardia in sepsis, the importance of rate control and the beneficial effects of beta-blockers.         Sepsis and Tachycardia – Aetiologic Factors During sepsis, the sympathetic nervous system plays a key role in maintaining cardiac output and blood pressure. This is achieved through cha1 Read more

Improving Haemodynamic Management of ICU Patients: Decatecholaminisation & Cardiac Stress Reduction

2022 08 Dec

A summary of a symposium organised by AOP Health with presentations from Ricard Ferrer, Vall d’Hebron University Hospital, Barcelona, Spain; Bruno Levy, Centre Hospitalier Universitaire de Nancy, CHU Nancy · Réanimation Médicale Brabois, France; and Michael Fries, St. Vincenz Krankenhaus Limburg, Department of Anesthesiology, Germany. 1 Read more

Short Acting Beta-Blockers in Critically Ill Patients With Heart Failure

2022 14 Oct

An overview of the clinical evidence demonstrating the effectiveness of landiolol for the treatment of atrial fibrillation or atrial flutter with heart failure and effective heart rate control during arrhythmias.   Supraventricular arrhythmias (SVTs) are common in post-operative and cardiac ICUs. SVTs increase the risk of deat1 Read more

Septic Shock and Vasopressor Initiation: Why Earlier is Better

2022 16 Mar

An overview of vasopressor management, current evidence and when to initiate vasopressor therapy for best possible patient outcome. Vasopressor management is a cornerstone in the haemodynamic management of septic shock for reversing hypotension by increasing systemic vascular resistance and improving organ perfusion. The Surviving Sepsis 1 Read more

Rationale Behind Practice: Landiolol in Critical Care

2022 16 Mar

A summary of data regarding the use of landiolol as a potential immunomodulator in septic patients and its effectiveness and safety in the management of new-onset postoperative atrial fibrillation (POAF). Cardiovascular Dysfunction and Sepsis Cardiovascular dysfunction is a common complication of sepsis. Approximately 40 to 50% of 1 Read more

Management of Acute Arrhythmias in Patients With Cardiac Dysfunction - Update of ESC Guidelines

2021 30 Sep

In 2020, the ultra-short acting beta-blocker landiolol was first included in the ESC guidelines with a class I recommendation. The recommendations were based on study results demonstrating the rapid response, efficacy, and safety of this drug. At a recent symposium, during 2021 Heart Failure World Congress, cardiologists were invited to presen1 Read more

Vasopressor Management in Septic Shock: General Overview and Personalised Approaches

2021 24 Jun

This article summarises the proceedings of an ESICM webinar in which two experts discuss vasopressor therapy and its fundamental role in the treatment of septic shock-induced hypotension. They provide an overview of severe septic shock, the benefits of second-line vasopressors and their use in COVID-19 patients. Vasopressors in Severe Se1 Read more

Evidence-Based Management of Atrial Fibrillation

2021 22 Feb

The 2020 ESC Guidelines and the addition of Landiolol An overview of the updated guidelines for the diagnosis and management of atrial fibrillation, developed in association with the European Association for Cardio-Thoracic Surgery. T he European Society of Cardiology (ESC) provides a range of scientific and educational activitie1 Read more

New ESC Guidelines for Atrial Fibrillation Published

2020 30 Nov

The European Society of Cardiology ( ESC ) has published their new guidelines for the diagnosis and treatment of atrial fibrillation during its congress this year*. The recently released guidelines replace the recommendations of the Society, which were published in 2016. One of the most interesting innovations is the approach towards character1 Read more

Treatment of Catecholamine Refractory Hypotension in Septic Shock: Beyond First Line Vasopressor

2020 24 Nov

Hypotension during septic shock is a strong indicator of patient outcome and mortality. Arginine vasopressin is a naturally produced human hormone with vasoconstriction effect via V1 receptor activation and a short 5-20 minutes half-life and is recommended by the Surviving Sepsis Campaign guidelines to be added as a second-line vasoactive agent w1 Read more

Atrial Fibrillation and Sepsis: A Life-Threatening Combination

2020 08 Oct

  Almost half of the patients with sepsis suffer from myocardial depression and a reduced ejection fraction. Sepsis can also cause changes in circulating volume, vascular tone, and coronary blood flow, all of which affect heart function and heart rate. Serum catecholamine levels and direct measurements of renal sympathetic nerve activity have s1 Read more

COVID-19 and the Potential Effects on the Cardiovascular System

2020 11 Aug

COVID-19 affects the myocardium and myocarditis and cardiac injury is a common condition among hospitalised patients. Landiolol, a new ultra-short acting, intravenous most  β 1 selective blocker, can help reduce inflammation and provide therapeutic benefits. Influenza, bacterial pneumonias, respiratory infections and viru1 Read more

Vasoactive Agent Management for Haemodynamic Support in COVID-19 Patients

2020 19 May

An overview of the Surviving Sepsis Guidelines for the vasoactive agent management of COVID-19 patients with septic shock and the use of arginine vasopressin in this patient population. The SARS-CoV-2 has caused a global health crisis. Thousands of people across the globe have been affected by COVID-19. Clinicians are in urgent need 1 Read more

AMOMED Pharma Offers Drugs for Severe COVID-19 Cases

2020 23 Apr

AMOMED Pharma develops medicinal products for patients suffering from septic shock at the intensive care units. Septic shock is a life-threatening complication in COVID-19 patients.   Most COVID-19 admissions to the intensive care unit are due to severe lung disorders requiring invasive mechanical ventilation; many with acute respiratory distr1 Read more

3 Practical Tools for the Daily Work in the ICU

2020 23 Apr

We created the following three practical tools for physicians and medical personnel for their daily work in the ICU related to COVID-19 and sepsis.   Recommendations for Vasoactive Management for Hemodynamic Support in COVID-19 Patients with Septic Shock SOFA Score WHO Categorization of Clinical Syndromes Associated with COVID-19 in Adults 1 Read more

New-Onset of Atrial Fibrillation in the ICU: a special challenge for heart failure patients

2020 23 Apr

Atrial fibrillation (AF) is the most common heartbeat irregularity and associated with development of stroke, myocardial infarction and heart failure. Vice versa, the structural and neurohormonal changes in heart failure (HF), when the contractility of the heart muscle is reduced, make the development and progression of AF much more likely.  HF it1 Read more

COVID-19 Online Resources for Health Care Professionals

2020 23 Apr

Below you can find a summarised overview of online resources with developments, guidelines and recommendations for physicians and medical staff for COVID-19 patients in critical condition (e.g. patients in intensive care), as well as other general resources. ICU Therapy guideline for the treatment of patients with a SARS CoV2 infection Auto1 Read more

Arginine Vasopressin in Septic Shock: The Multimodal Approach for Early Blood Pressure Restoration

Change content default value Read more

Tachycardia in Sepsis – First You Need It, Then You Don't

Change content default value Read more

Sofia Opitz is Managing Director of AOP Health Nordics

Sofia Opitz has joined AOP Orphan Pharmaceuticals GmbH as Nordic Managing Director. She has more than 25-years of experience in the Nordic pharmaceutical markets and prior to joining AOP Health she worked as Country Manager for Sweden, Norway, and Denmark at BIOCODEX.     Achieving ambitious goals   Opitz started her career as 1 Read more

LANDI-UP: Strengthening Confidence in Landiolol for Real-World ICU and Critical Care

2026 10 Mar

The LANDI-UP study provides the first European real-world evidence of landiolol use in critically ill patients with supraventricular arrhythmias. This landmark multicentre observational study demonstrates that landiolol achieves effective heart rate control with minimal haemodynamic impact, confirming its safety and efficacy across diverse Europ1 Read more

Vasopressin in 2025: Emerging Data Converge on Earlier, Smarter Intervention

2025 03 Dec

Vasopressin, an adjunctive vasopressor agent in septic shock, is increasingly supported by evidence favouring early, targeted intervention. Recent research, from mechanistic reviews to artificial intelligence-driven modelling, converges on a coherent strategy: initiate vasopressin earlier, at lower norepinephrine doses, and before severe metabol1 Read more

Redefining Rate Control Strategy With Landiolol: Manage the Rhythm Without Compromising the System

2025 14 Oct

Landiolol, an ultra-short-acting and highly β1-selective intravenous β-blocker, addresses the need for rapid and controllable arrhythmia suppression while maintaining cardiovascular stability. Recently approved in the United States and already in use in Europe, landiolol combines rapid onset and offset with a favourable haemodynamic profile. 1 Read more

Vasopressin in Septic Shock: New Insights on Timely Addition to Norepinephrine

2025 24 Jul

Early vasopressin initiation in septic shock may improve outcomes beyond the current practice of waiting for higher norepinephrine doses. Recent studies suggest starting AVP earlier can reduce shock duration and hospital mortality. Despite AVP often being started late, a proactive, protocol-driven approach that considers Nor dose, duration, and 1 Read more

Advancing Cardiovascular Management in Critical Care: A Focus on Vasopressors and Beta-Blockers

2025 20 May

Clinical insights on the use of beta-blockers and vasopressors in the ICU, focusing on landiolol and vasopressin.   When managing cardiovascular instability in critically ill patients, intensivists often face a delicate balancing act: controlling heart rate without compromising haemodynamics and maintaining perfusion without excessive va1 Read more

Rethinking Septic Shock Management: Potential of Early Vasopressin Use to Enhance Patient Outcomes

2024 28 Nov

Vasopressin timing, patient selection, optimal vasopressin use in septic shock, and potential mortality benefits in selected patient populations.   Septic Shock Overview and Current Treatments Septic shock is a severe, life-threatening response to infection, characterised by systemic inflammation, tissue hypoperfusion, and persisten1 Read more

ESICM Webinar – Cardiovascular Management After Surgery

2024 01 Oct

  In a webinar at the ESICM Congress, Dr Aretha and Dr Garcia-Alvarez spoke about cardiovascular management after surgery. More specifically, Dr Aretha spoke about the management of post-operative atrial fibrillation, and Dr Garcia-Alvarez spoke about the importance of early application of vasopressin in septic shock patients.   Mana1 Read more

Introduction to Landiolol in Acute Cardiac Care

2024 12 Mar

  An overview of landiolol, a potent and cardioselective beta-blocker offering a promising addition to the armamentarium for managing acute cardiac conditions for rapid and effective rate control with minimal adverse effects.   Cardiac emergencies present complex challenges in emergency medical settings, requiring prompt and effective ma1 Read more

Cardiovascular Management in Septic Shock: Optimising Vascular and Cardiac Function

2023 30 Nov

An overview of vasopressor management, current evidence on its use, when to initiate vasopressor therapy for best possible patient outcome and a discussion regarding the use of landiolol in septic patients with persistent tachycardia.    Optimising Vasopressin Initiation in Septic Shock   Patients with septic shock, and especially1 Read more

Cardiovascular Management in Sepsis: Improving Cardiac and Vascular Functions

2023 13 Oct

Vasopressin and landiolol are critical therapies for ensuring the vascular and cardiac systems are as close to optimal conditions as possible during septic shock. Better cardiovascular management in septic shock can help improve septic shock management.     Sepsis is a life-threatening organ dysfunction caused by a dysregulated host resp1 Read more

Tachycardia in Sepsis: Friend or Foe?

2023 13 Mar

An overview of tachycardia in sepsis, the importance of rate control and the beneficial effects of beta-blockers.         Sepsis and Tachycardia – Aetiologic Factors During sepsis, the sympathetic nervous system plays a key role in maintaining cardiac output and blood pressure. This is achieved through cha1 Read more

Improving Haemodynamic Management of ICU Patients: Decatecholaminisation & Cardiac Stress Reduction

2022 08 Dec

A summary of a symposium organised by AOP Health with presentations from Ricard Ferrer, Vall d’Hebron University Hospital, Barcelona, Spain; Bruno Levy, Centre Hospitalier Universitaire de Nancy, CHU Nancy · Réanimation Médicale Brabois, France; and Michael Fries, St. Vincenz Krankenhaus Limburg, Department of Anesthesiology, Germany. 1 Read more

Short Acting Beta-Blockers in Critically Ill Patients With Heart Failure

2022 14 Oct

An overview of the clinical evidence demonstrating the effectiveness of landiolol for the treatment of atrial fibrillation or atrial flutter with heart failure and effective heart rate control during arrhythmias.   Supraventricular arrhythmias (SVTs) are common in post-operative and cardiac ICUs. SVTs increase the risk of deat1 Read more

Septic Shock and Vasopressor Initiation: Why Earlier is Better

2022 16 Mar

An overview of vasopressor management, current evidence and when to initiate vasopressor therapy for best possible patient outcome. Vasopressor management is a cornerstone in the haemodynamic management of septic shock for reversing hypotension by increasing systemic vascular resistance and improving organ perfusion. The Surviving Sepsis 1 Read more

Rationale Behind Practice: Landiolol in Critical Care

2022 16 Mar

A summary of data regarding the use of landiolol as a potential immunomodulator in septic patients and its effectiveness and safety in the management of new-onset postoperative atrial fibrillation (POAF). Cardiovascular Dysfunction and Sepsis Cardiovascular dysfunction is a common complication of sepsis. Approximately 40 to 50% of 1 Read more

Management of Acute Arrhythmias in Patients With Cardiac Dysfunction - Update of ESC Guidelines

2021 30 Sep

In 2020, the ultra-short acting beta-blocker landiolol was first included in the ESC guidelines with a class I recommendation. The recommendations were based on study results demonstrating the rapid response, efficacy, and safety of this drug. At a recent symposium, during 2021 Heart Failure World Congress, cardiologists were invited to presen1 Read more

Vasopressor Management in Septic Shock: General Overview and Personalised Approaches

2021 24 Jun

This article summarises the proceedings of an ESICM webinar in which two experts discuss vasopressor therapy and its fundamental role in the treatment of septic shock-induced hypotension. They provide an overview of severe septic shock, the benefits of second-line vasopressors and their use in COVID-19 patients. Vasopressors in Severe Se1 Read more

Evidence-Based Management of Atrial Fibrillation

2021 22 Feb

The 2020 ESC Guidelines and the addition of Landiolol An overview of the updated guidelines for the diagnosis and management of atrial fibrillation, developed in association with the European Association for Cardio-Thoracic Surgery. T he European Society of Cardiology (ESC) provides a range of scientific and educational activitie1 Read more

Treatment of Catecholamine Refractory Hypotension in Septic Shock: Beyond First Line Vasopressor

2020 24 Nov

Hypotension during septic shock is a strong indicator of patient outcome and mortality. Arginine vasopressin is a naturally produced human hormone with vasoconstriction effect via V1 receptor activation and a short 5-20 minutes half-life and is recommended by the Surviving Sepsis Campaign guidelines to be added as a second-line vasoactive agent w1 Read more

COVID-19 and the Potential Effects on the Cardiovascular System

2020 11 Aug

COVID-19 affects the myocardium and myocarditis and cardiac injury is a common condition among hospitalised patients. Landiolol, a new ultra-short acting, intravenous most  β 1 selective blocker, can help reduce inflammation and provide therapeutic benefits. Influenza, bacterial pneumonias, respiratory infections and viru1 Read more

Vasoactive Agent Management for Haemodynamic Support in COVID-19 Patients

2020 19 May

An overview of the Surviving Sepsis Guidelines for the vasoactive agent management of COVID-19 patients with septic shock and the use of arginine vasopressin in this patient population. The SARS-CoV-2 has caused a global health crisis. Thousands of people across the globe have been affected by COVID-19. Clinicians are in urgent need 1 Read more

Arginine Vasopressin in Septic Shock: The Multimodal Approach for Early Blood Pressure Restoration

Change content default value Read more

Tachycardia in Sepsis – First You Need It, Then You Don't

Change content default value Read more

Less is More in Shock Management

2025 06 May

Permissive hypotension, phenotyping shock, vasopressor selection and timing, and emerging interest in beta-blockade for septic patients.   It is important to reconsider conventional aggressive approaches to shock management and explore the evolving concept of permissive hypotension. There is a need to avoid reflexively treating all hypot1 Read more

Rationale for Early Arginine-Vasopressin Administration

2025 27 Mar

The basics of vasopressor support and advanced considerations regarding its early use in intensive care settings.   Introduction The use of vasopressors in critical care is a crucial aspect of haemodynamic management. While norepinephrine remains the primary agent of choice, the role of other vasopressors such as vasopressin has ga1 Read more